This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Zydelig
  • /
  • A Phase 2, Open-Label Study Evaluating the Efficac...
Clinical trial

A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Combination With Idelalisib in Subjects With Relapsed or Refractory Hematologic Malignancies

Read time: 2 mins
Last updated:1st Jun 2013
Identifier: NCT01796470
This study will evaluate the efficacy, safety, tolerability, and pharmacodynamics of entospletinib and idelalisib. Participants will be enrolled who have one of the following hematological tumor types: chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), or non-FL indolent non-Hodgkin lymphomas (iNHL; including lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia [LPL/WM], small lymphocytic lymphoma [SLL], or marginal zone lymphoma [MZL]).
Category Value
Date last updated at source 2017-01-20
Study type(s) Interventional
Expected enrolment 66
Study start date 2013-06-01
Estimated primary completion date 2016-12-01

View full details